Plasma-derived exosomal miRNA profiles associated with type 1 diabetes
© 2024 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd..
AIMS: Recently, exosomal miRNAs have been shown to play important roles in multiple diseases, including type 1 diabetes (T1D). To assess the biomarker potential of exosomal miRNAs for T1D, we measured the expression profiles of plasma-derived exosomal miRNAs in T1D and explored their potential functions by bioinformatic analysis.
MATERIALS AND METHODS: In the discovery phase, exosome samples were isolated from plasma by size exclusion chromatography from 10 T1D patients and 10 sex- (p = 0.36), age- (p = 0.97), and body mass index-matched (p = 0.47) healthy control subjects. Exosomal miRNA expression profiles were measured using the Illumina NovaSeq 6000 platform. With verification by quantitative real-time PCR (qRT-PCR), we used multiple bioinformatics approaches to explore the potential biological functions of the identified differentially expressed miRNAs. The diagnostic signature of exosomal miRNAs was evaluated by least absolute shrinkage and selection operator (LASSO) regression and evaluated based on the area under the receiver operating characteristic curve (AUC).
RESULTS: In total, 43 differentially expressed miRNAs, among which 34 were upregulated and 9 were downregulated, were identified in T1D. After correcting for multiple testing using false discovery rate, 11 identified exosomal miRNAs still showed statistical significance. Among the 5 selected miRNAs, 3 miRNAs (miR-103a-3p, miR-144-5p and miR-454-3p) were successfully validated by qRT-PCR. The biological analysis-enriched terms included protein autophosphorylation and the Hedgehog signalling pathway. The highest AUC of exosomal miRNA was 0.889 under the LASSO model. The expression levels of 5 selected exosomal miRNAs were correlated with multiple clinical characteristics such as fasting C-peptide and postprandial C-peptide.
CONCLUSIONS: Our results indicated that plasma-derived exosomal miRNAs could serve as promising diagnostic biomarkers of T1D.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Diabetes/metabolism research and reviews - 40(2024), 2 vom: 01. Feb., Seite e3774 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pang, Haipeng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bioinformatic analysis |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/dmrr.3774 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368295680 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368295680 | ||
| 003 | DE-627 | ||
| 005 | 20240214233333.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240211s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/dmrr.3774 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM368295680 | ||
| 035 | |a (NLM)38340050 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pang, Haipeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma-derived exosomal miRNA profiles associated with type 1 diabetes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd. | ||
| 520 | |a AIMS: Recently, exosomal miRNAs have been shown to play important roles in multiple diseases, including type 1 diabetes (T1D). To assess the biomarker potential of exosomal miRNAs for T1D, we measured the expression profiles of plasma-derived exosomal miRNAs in T1D and explored their potential functions by bioinformatic analysis | ||
| 520 | |a MATERIALS AND METHODS: In the discovery phase, exosome samples were isolated from plasma by size exclusion chromatography from 10 T1D patients and 10 sex- (p = 0.36), age- (p = 0.97), and body mass index-matched (p = 0.47) healthy control subjects. Exosomal miRNA expression profiles were measured using the Illumina NovaSeq 6000 platform. With verification by quantitative real-time PCR (qRT-PCR), we used multiple bioinformatics approaches to explore the potential biological functions of the identified differentially expressed miRNAs. The diagnostic signature of exosomal miRNAs was evaluated by least absolute shrinkage and selection operator (LASSO) regression and evaluated based on the area under the receiver operating characteristic curve (AUC) | ||
| 520 | |a RESULTS: In total, 43 differentially expressed miRNAs, among which 34 were upregulated and 9 were downregulated, were identified in T1D. After correcting for multiple testing using false discovery rate, 11 identified exosomal miRNAs still showed statistical significance. Among the 5 selected miRNAs, 3 miRNAs (miR-103a-3p, miR-144-5p and miR-454-3p) were successfully validated by qRT-PCR. The biological analysis-enriched terms included protein autophosphorylation and the Hedgehog signalling pathway. The highest AUC of exosomal miRNA was 0.889 under the LASSO model. The expression levels of 5 selected exosomal miRNAs were correlated with multiple clinical characteristics such as fasting C-peptide and postprandial C-peptide | ||
| 520 | |a CONCLUSIONS: Our results indicated that plasma-derived exosomal miRNAs could serve as promising diagnostic biomarkers of T1D | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bioinformatic analysis | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a exosomes | |
| 650 | 4 | |a miRNA | |
| 650 | 4 | |a plasma-derived | |
| 650 | 4 | |a type 1 diabetes | |
| 650 | 7 | |a C-Peptide |2 NLM | |
| 650 | 7 | |a Hedgehog Proteins |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 700 | 1 | |a Fan, Wenqi |e verfasserin |4 aut | |
| 700 | 1 | |a Pi, Linhua |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Xiajie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Shuoming |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Gan |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Zhiguo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Zhiguang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes/metabolism research and reviews |d 1999 |g 40(2024), 2 vom: 01. Feb., Seite e3774 |w (DE-627)NLM102947112 |x 1520-7560 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:e3774 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/dmrr.3774 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2024 |e 2 |b 01 |c 02 |h e3774 | ||